title: Experimental isolation and transplantation of hepatocytes with the use of antibody against interleukin-2 receptor (daclizumab) as immunosuppressive agent.
abstract: BACKGROUND
  Daclizumab (Dmab) is a genetically engineered humanized IgG1 monoclonal antibody that binds to the alpha chain of the interleukin-2 receptor (Tac, CD25, p55) expressed on activated human T lymphocytes. Dmab has been used in a clinical protocol of islet transplantation with satisfactory results. The aim of the present study was to evaluate the use of an antibody against the interleukin-2 receptor (Dmab) as an immunosuppressive agent in an experimental model of hepatocyte allotransplantation (allo-Tx) in rats with fulminant hepatic failure (FHF).
  
  
  METHODS
  Six Wistar rats were used as donors and 48 Lewis rats as recipients: four groups of 12 animals each with induction of FHF and 24 hour later hepatocyte Tx--group A: no treatment; group B: cyclosporin (20 mg/kg days 0 to 5 and 10 mg/kg days 6 to 15); group C: Dmab (0.05 mg day of Tx and 0.05 mg day 7); and group D: Dmab and cyclosporine. Hepatocytes were transplanted intrasplenically. Animals were followed for 15 days.
  
  
  RESULTS
  Statistical analysis showed better survival among groups C (83%, MST = 13) and D (92%, MST = 14.25) compared to groups A (max 72, MST = 1.5) or B (50%, MST = 9). Survival in group D was better but not significantly than group C. Biochemical evaluation and histology confirmed satisfactory function and engraftment, respectively.
  
  
  CONCLUSIONS
  This experimental model showed the safe, effective use of Dmab.
authors.affiliation: Department of Surgery, E. Dynan Hospital, Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Tsiolis
authors.forename: A
authors.initials: A
authors.lastname: Papalois
authors.forename: I
authors.initials: I
authors.lastname: Loukopoulos
authors.forename: A
authors.initials: A
authors.lastname: Gravvanis
authors.forename: E
authors.initials: E
authors.lastname: Lykoudis
authors.forename: E
authors.initials: E
authors.lastname: Theodossopoulou
authors.forename: A
authors.initials: A
authors.lastname: Chairakakis
authors.forename: D
authors.initials: D
authors.lastname: Dimitroulopoulos
authors.forename: I
authors.initials: I
authors.lastname: Sfiniadakis
authors.forename: I
authors.initials: I
authors.lastname: Vassiliou
authors.forename: E
authors.initials: E
authors.lastname: Felekouras
authors.forename: P
authors.initials: P
authors.lastname: Dedeilias
authors.forename: M
authors.initials: M
authors.lastname: Kontogiorgi
authors.forename: L
authors.initials: L
authors.lastname: Papadimitriou
authors.forename: I
authors.initials: I
authors.lastname: Papadimitriou
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D006085:Graft Survival; D022781:Hepatocytes / Q000166:cytology* / Q000637:transplantation*; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017114:Liver Failure, Acute / Q000601:surgery*; D008297:Male; D023421:Models, Animal; D051381:Rats; D011917:Rats, Inbred Lew; D017208:Rats, Wistar; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013154:Spleen; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab